Evra

Evra is a transdermal contraceptive patch developed by the pharmaceutical company Wyeth (now part of Pfizer) and approved by the U.S. Food and Drug Administration (FDA) in 2002. It is one of several non-hormonal and hormonal birth control methods available, designed to provide long-term contraception with minimal daily effort. The patch is a small, adhesive square that delivers a combination of ethinyl estradiol and norelgestromin through the skin, providing continuous hormone exposure to prevent ovulation, thicken cervical mucus, and thin the uterine lining.

Evra is applied weekly to clean, dry skin on the upper outer arm, buttocks, abdomen, or upper torso, with a new patch every seven days for three weeks followed by a four-day patch-free interval. This cycle mimics the natural hormonal fluctuations of the menstrual cycle. Unlike oral contraceptives, Evra does not require ingestion, making it convenient for individuals who struggle with compliance or have nausea associated with pill-based methods.

Common side effects may include breast tenderness, nausea, headaches, and mild skin irritation at the application site. Less common but potentially serious side effects include blood clots, high blood pressure, and liver problems, which require medical supervision. Evra is not suitable for everyone, including those with a history of blood clots, liver disease, or certain hormonal conditions. It should not be used by individuals under 18 years old or those who smoke, as smoking increases the risk of cardiovascular complications.

Evra is typically covered by many insurance plans, though coverage may vary. It is important to consult a healthcare provider to determine eligibility, discuss potential risks, and explore alternatives if needed. As with any contraceptive method, regular follow-ups and open communication with a healthcare professional are essential for optimal effectiveness and safety.